Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.06
CTIC's Cash to Debt is ranked lower than
78% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CTIC: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
CTIC' s 10-Year Cash to Debt Range
Min: 0.01  Med: 1.22 Max: No Debt
Current: 1.06
Equity to Asset -0.16
CTIC's Equity to Asset is ranked lower than
94% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CTIC: -0.16 )
Ranked among companies with meaningful Equity to Asset only.
CTIC' s 10-Year Equity to Asset Range
Min: -2.7  Med: -0.03 Max: 0.95
Current: -0.16
-2.7
0.95
F-Score: 3
Z-Score: -39.81
M-Score: -5.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -147.85
CTIC's Operating margin (%) is ranked lower than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CTIC: -147.85 )
Ranked among companies with meaningful Operating margin (%) only.
CTIC' s 10-Year Operating margin (%) Range
Min: -123250  Med: -676.02 Max: -119.75
Current: -147.85
-123250
-119.75
Net-margin (%) -160.52
CTIC's Net-margin (%) is ranked lower than
59% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CTIC: -160.52 )
Ranked among companies with meaningful Net-margin (%) only.
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75  Med: -852.53 Max: -123.26
Current: -160.52
-169773.75
-123.26
ROE (%) -663.08
CTIC's ROE (%) is ranked lower than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CTIC: -663.08 )
Ranked among companies with meaningful ROE (%) only.
CTIC' s 10-Year ROE (%) Range
Min: -1010.2  Med: -93.55 Max: -42.02
Current: -663.08
-1010.2
-42.02
ROA (%) -139.17
CTIC's ROA (%) is ranked lower than
89% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CTIC: -139.17 )
Ranked among companies with meaningful ROA (%) only.
CTIC' s 10-Year ROA (%) Range
Min: -261.37  Med: -90.98 Max: -20.35
Current: -139.17
-261.37
-20.35
ROC (Joel Greenblatt) (%) -1859.54
CTIC's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CTIC: -1859.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2180.72  Med: -1263.05 Max: -48.38
Current: -1859.54
-2180.72
-48.38
EBITDA Growth (3Y)(%) -29.40
CTIC's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CTIC: -29.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.5  Med: -29.00 Max: 50.1
Current: -29.4
-71.5
50.1
EPS Growth (3Y)(%) -43.10
CTIC's EPS Growth (3Y)(%) is ranked lower than
89% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CTIC: -43.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIC' s 10-Year EPS Growth (3Y)(%) Range
Min: -74.4  Med: -27.00 Max: 64
Current: -43.1
-74.4
64
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CTIC Guru Trades in Q3 2014

Jim Simons 1,010,871 sh (+45.94%)
» More
Q4 2014

CTIC Guru Trades in Q4 2014

Jim Simons 587,916 sh (-41.84%)
» More
Q1 2015

CTIC Guru Trades in Q1 2015

Paul Tudor Jones 86,900 sh (New)
Jim Simons Sold Out
» More
Q2 2015

CTIC Guru Trades in Q2 2015

Jim Simons 561,124 sh (New)
Paul Tudor Jones 68,600 sh (-21.06%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 4.21
CTIC's P/S is ranked higher than
76% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CTIC: 4.21 )
Ranked among companies with meaningful P/S only.
CTIC' s 10-Year P/S Range
Min: 0.06  Med: 230.46 Max: 40559.92
Current: 4.21
0.06
40559.92
Current Ratio 1.93
CTIC's Current Ratio is ranked lower than
75% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CTIC: 1.93 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s 10-Year Current Ratio Range
Min: 0.38  Med: 2.82 Max: 24.99
Current: 1.93
0.38
24.99
Quick Ratio 1.82
CTIC's Quick Ratio is ranked lower than
71% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CTIC: 1.82 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s 10-Year Quick Ratio Range
Min: 0.38  Med: 2.82 Max: 24.96
Current: 1.82
0.38
24.96
Days Inventory 1.00
CTIC's Days Inventory is ranked higher than
99% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CTIC: 1.00 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s 10-Year Days Inventory Range
Min: 16.31  Med: 663.33 Max: 8925.18
Current: 1
16.31
8925.18
Days Sales Outstanding 5.25
CTIC's Days Sales Outstanding is ranked higher than
93% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CTIC: 5.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s 10-Year Days Sales Outstanding Range
Min: 2.47  Med: 68.68 Max: 1460
Current: 5.25
2.47
1460

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.02
CTIC's Price/Median PS Value is ranked higher than
99% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CTIC: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
CTIC' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 2.13 Max: 5782.18
Current: 0.02
0.02
5782.18
Earnings Yield (Greenblatt) (%) -35.17
CTIC's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CTIC: -35.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -36.57  Med: 0.00 Max: 0
Current: -35.17
-36.57
0

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 38 8
EPS($) -0.54 -0.78
EPS without NRI($) -0.54 -0.78

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CTIC.Italy, 0QUJ.UK, CEPR.Germany,
CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is engaged in commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 

More From Other Websites
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 27 2015
Falling Earnings Estimates Signal Weakness Ahead for CTI BioPharma (CTIC) Aug 26 2015
CTI BIOPHARMA CORP Financials Aug 15 2015
10-Q for CTI BioPharma Corp. Aug 08 2015
Edited Transcript of CTIC earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
CTI BioPharma reports 2Q loss Aug 06 2015
CTI BioPharma reports 2Q loss Aug 06 2015
CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Aug 06 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 06 2015
CTI BioPharma Reports Second Quarter 2015 Financial Results Aug 06 2015
Q2 2015 CTi Biopharma Corp Earnings Release - After Market Close Aug 06 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jul 30 2015
CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 Jul 28 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Jul 27 2015
CTI BioPharma Appoints Bruce J. Seeley As Executive Vice President and Chief Commercial Officer Jul 27 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 30 2015
3 Biotech Stocks Under $10 to Trade for Breakouts Jun 18 2015
Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In... Jun 15 2015
Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of... Jun 12 2015
CTI BIOPHARMA CORP Files SEC form 8-K/A, Other Events Jun 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK